Demographic character | Methodological character | ||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Study | ASD group | TD group | Value | ROI tract | |||||||||||||||||||||||||
N a | Males | Mean age (years) | IQb | N c | Males | Mean age (years) | IQb | Diagnostic tools | Medication / comorbidity | Tesla | B factor | Number of direction | NEX | TE/TR (ms) | Type of WBA | FA | MD | RD | AD | ADC | CC | UF | Cg | SLF | ILF | IFOF | Fo | AF | |
Whole brain voxel-wise analysis study | |||||||||||||||||||||||||||||
Alexander and colleagues [24] | 43 | 43 | 16.2 | 107 | 34 | 34 | 16.4 | 113 | DSM-IV/ICD-10/ADI-R/ADOS-G | Yes/Yes | 3 | 1,000 | 12 | 4 | 84/7,000 | ROI | ○ | ○ | ○ | ○ | × | ○ | × | × | × | × | × | × | × |
Ameis and colleagues [43] | 19 | 16 | 12.4 | 98.5 | 16 | 8 | 12.3 | 101 | DSM-IV/ADI-R/ADOS | No/No | 3 | 1,250 | 12 | 5 | 80/4,100 | ROI | ○ | ○ | × | × | × | ○ | × | ○ | ○ | × | × | × | × |
Beacher and colleagues [58] | 28 | 15 | 32 | NA | 30 | 15 | 30 | NA | DSM-IV | Yes/No | 1.5 | 1,000 | 64 | NA | 95/8,000 | ROI | ○ | × | × | × | × | ○ | × | × | × | × | × | × | × |
Ben Bashat and colleagues [64] | 17 | NA | NA | NA | NA | NA | 9.6 | NA | DSM-IV/ADI-R/ADOS | NA/NA | 1.5 | 6,000 | 6 | 4 | 128/1,800 | ROI | ○ | ○ | × | × | × | ○ | × | ○ | ○ | × | × | × | × |
Brito and colleagues [32] | 8 | 8 | 9.53 | NA | 8 | 8 | 9.57 | NA | DSM-IV | Yes/No | 1.5 | 100 | 12 | 3 | 90/3,100 | ○ | × | × | × | × | ○ | × | × | × | × | × | × | × | |
Catani and colleagues [67] | 15 | 15 | 31 | 109 | 16 | 16 | 35 | 120 | ICD-10/ADI/ADOS | NA/No | 1.5 | 1,300 | 64 | NA | 107/1,500 | Tractography | ○ | ○ | × | × | × | ○ | × | ○ | × | ○ | × | × | × |
Cheon and colleagues [62] | 17 | 17 | 11 | 112 | 17 | 17 | 10.2 | 114 | DSM-IV/ ADI-R/ADOS | Yes/No | 1.5 | 900 | 30 | 2 | 86/6500 | ROI | ○ | ○ | × | × | × | × | × | × | × | × | × | × | × |
Conturo and colleagues [74] | 17 | 14 | 26.5 | 104 | 17 | 14 | 26.1 | 105 | ADI-R/ADOS | Yes/No | 1.5 | NA | 7 | 10 | 94/1,51750 | Tractography | ○ | ○ | ○ | ○ | × | ○ | ○ | × | × | ○ | × | × | × |
Fletcher and colleagues [59] | 10 | 10 | 14.3 | 106 | 10 | 10 | 13.4 | 108 | DSM-IV/ICD-10/ADI-R/ADOS | NA/NA | 3 | 1,000 | 12 | 4 | 84/700 | ROI | × | × | × | × | × | × | × | × | × | × | × | × | × |
Hong and colleagues [60] | 18 | 18 | 8.69 | 105 | 16 | 16 | 9.81 | 106 | DSM-IV/ADI-R | No/No | 1.5 | 1,000 | 15 | 2 | 104.4/8,000 | ROI | ○ | × | × | × | ○ | ○ | × | × | × | × | × | × | × |
Ingalhalikar and colleagues [69] | 45 | 42 | 10.5 | NA | 30 | 14 | 10.3 | NA | NA | NA/NA | 3 | 1,000 | 15 | NA | 70/16,900 | ROI | ○ | × | × | × | × | × | × | × | ○ | × | × | × | × |
Knaus and colleagues [66] | 14 | 14 | 16.1 | 103 | 20 | 20 | 14.1 | 116 | DSM-IV/ADI-ADOS | NA/No | 3 | 1,000 | 15 | NA | N/A | Tractography | ○ | × | × | × | × | × | × | × | × | × | × | × | ○ |
Kumar and colleagues [26] | 32 | 29 | 5 | NA | 16 | 12 | 5.5 | Na | DSM-IV | NA/No | 3 | 1,000 | 6 | 6 | 79/10,000 | Tractography | ○ | × | × | × | ○ | ○ | ○ | ○ | × | × | ○ | × | ○ |
Langen and colleagues [73] | 21 | 21 | 25.6 | 107 | 22 | 22 | 28.5 | 110 | ICD-10/ADI-R/ADOS | No/No | 3 | 1,300 | 32 | NA | 107/10,000 | Tractography | ○ | ○ | ○ | ○ | × | × | × | × | × | × | × | × | × |
Leemans and Jones [78] | 43 | 43 | 16.2 | 108 | 34 | 34 | 16.4 | 113 | DSM-IV/ICD-10/ADI-R/ADOS-G | NA/No | 3 | 1,000 | 12 | 3 | 84/7,000 | ROI | ○ | ○ | ○ | ○ | × | × | × | × | × | × | × | × | × |
Lo and colleagues [25] | 15 | 15 | 15.2 | 108 | 15 | NA | 15 | 111 | DSM-IV/ICD-10/ADI-R | NA/No | 3 | 6,000/4,000 | 102 | NA | 142/9,100, 130/9,600 | ROI | ○ | × | × | × | × | ○ | ○ | ○ | × | × | × | × | ○ |
Poustka and colleagues [63] | 18 | 16 | 19.7 | 111 | 18 | 16 | 9.7 | 113 | ICD-10/ADI/ADOS | NA/No | 1.5 | 1,000 | 6 | 15 | 78/4,700 | ROI | ○ | × | × | × | × | ○ | ○ | × | ○ | × | × | ○ | × |
Pugliese and colleagues [57] | 24 | 24 | 23.3 | 105 | 24 | 24 | 25.3 | 121 | ICD-10/ADI-R | No/No | NA | 1,300 | 32 | NA | 107/15,000 | Tractography | ○ | ○ | × | × | × | × | ○ | ○ | × | ○ | ○ | ○ | × |
Sahyoun and colleagues [71] | 9 | 7 | 12.8 | 101 | 12 | 9 | 13.3 | 106 | ADIM-IV/ADI-R | No/No | 3 | 700 | 60 | Na | 84/7,980 | ROI | ○ | × | × | × | × | × | × | × | × | × | × | × | × |
Shukla and colleagues [65] | 24 | 24 | 5 | NA | 16 | 12 | 5.9 | NA | ADI-R/ADOS | Yes/No | 3 | 200 | 15 | 4 | 99.4/1,0000 | ROI | ○ | ○ | ○ | × | ○ | × | × | × | × | × | × | × | |
Sivaswamy and colleagues [68] | 27 | 24 | 5 | NA | 16 | 12 | 5.9 | NA | DSM-IV | Yes/No | 3 | 1,000 | 6 | 6 | 160/11000 | ROI | ○ | × | × | × | × | × | × | × | × | × | × | × | × |
Sundaram and colleagues [72] | 50 | 43 | 4.79 | NA | 16 | 11 | 6.84 | NA | DSM-IV0 | Yes/No | 3 | 1,000 | 6 | 6 | 79/10,000 | Tractography | ○ | × | × | × | ○ | × | × | × | × | × | × | × | × |
Thomas and colleagues [28] | 12 | 12 | 28.5 | 107 | 18 | 18 | 22.4 | 112 | DSM-IV/ ADI-R/ADOS | NA/No | 3 | 850 | 6 | 12 | 82/4,900 | ROI | ○ | × | × | × | × | × | ○ | × | × | ○ | ○ | × | × |
Verhoeven and colleagues [61] | 19 | 16 | 13.8 | NA | 33 | 24 | 12.9 | NA | DSM-IV | Yes/No | 3 | 800 | 45 | 2 | 55/11,043 | Tractography | ○ | × | × | × | ○ | × | × | × | ○ | × | × | × | × |
Weinstein and colleagues [27] | 22 | NA | 3.2 | NA | 28 | NA | 3.6 | NA | DSM-IV ADI-R/ADOS | NA/Yes | 1.5 | 1,000 | 15 | 2 | 94/11,043 | Tractography | ○ | ○ | ○ | ○ | × | ○ | × | ○ | ○ | × | × | × | × |